The article highlights the potentially game-changing approach of the Company towards treating Alzheimer’s Disease, based on technology developed at Rutgers by Dr. Luciano D’Adamio, PhD, MD, New Jersey ...
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...
A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 dose Results from OVATION 2 Study continue to validate TheraPlas® ...
Cybersecurity company SailPoint opened for trading on Thursday, returning to the markets more than two years after it went private.Maximize ...
Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.
Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...
Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...
IBD Aware, a wearable medical device in development for patients with inflammatory bowel disease, aims to improve disease ...
The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference p ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback